Previous Close | 16.73 |
1-Year Change | -32.97% |
6-Months Change | -31.6% |
3-Months Change | -23.15% |
Moving Avg (50d) | 19.168 |
Moving Avg (200d) | 23.572 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.64B |
Beta (3-Years) | 2.05 |
Revenue Growth (ttm) | 223.61% |
Net Profit Margin (ttm) | -1379.15% |
Return On Assets (ttm) | -42.7% |
EPS (ttm) | -5.48 |
PE Ratio (ttm) | -3.05 |
Dividend Yield | % |
Asset Description: | Intellia Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-10-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
16.395 | 15.893 | 15.559 | 15.057 | 14.22 | 13.384 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues.... Wikipedia